TexasRelating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy.
What it does
Plain-language analysis is being updated.
Use the official record and source text while enrichment finishes.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2025
- May 12Laid on the table subject to callLatest
- May 12Companion considered in lieu of
- May 12Postponed
- May 12Laid out as postponed business
- May 9Postponed
- May 9Laid out as postponed business
- May 7Postponed
- May 7Laid out as postponed business
- May 5Postponed
- May 5Read 2nd timeMinor
- May 2Placed on General State Calendar
- Apr 30Considered in Calendars
- Apr 25Committee report sent to Calendars
- Apr 23Committee report distributed
- Apr 23Comte report filed with Committee CoordinatorMinor
- Apr 14Reported favorably w/o amendment(s)Minor
- Apr 14Considered in public hearing
- Apr 7Left pending in committee
- Apr 7Testimony taken/registration(s) recorded in committee
- Apr 7Considered in public hearing
- Mar 26Referred to Public HealthMinor
- Mar 26Read first timeMinor
- Mar 4FiledIntroduced